Printer Friendly

Graft-versus-host disease market to reach $409 m in four years.

NEW YORK, N.Y., September 29, 2014 -- The graft versus host disease (GVHD) market was valued at $297 million in 2013, and is expected to increase to $409 million in 2018 at a CAGR of 6.61 percent, according to a report published in August.

The main drivers of growth in graft versus host disease over the 2013-2018 forecast period include the increasing numbers of allogeneic hematopoietic stem cell transplants and the increasing use of biologic off-label and marketed therapies.

Sanofi is a key player in the GVHD market with Thymoglobuline and Lemtrada by infiltrating prophylaxis, aGVHD and cGVHD.

J&J's Remicade, has gained a significant patent share of the aGVI ID patient group, as it is one of the few drugs that are efficient in GVHD with G1 involvement.

Gaining more and more ground in the treatment management of cGVHD is Roche's Rituxan that GlobalData estimates will be one of the bestselling biologies in GVHD in the U.S. by 2018.

Despite the vast array of available off-label therapies for the treatment and/or prevention of GVHD, very few of these therapies have been tested in large randomized trials.

This results in vague treatment recommendations and many patients being enrolled in institutional clinical trials. The only available standard of care is intravenous methylprednisolone that fails to produce a complete response in more than 50 percent of treated patients.

Steroid-refractory subgroups face low prognosis with deteriorating quality of life.

Second and third life treatments can vary from country to country but also between different medical institutions in the same country.

Key insights:

* High uptake of off-label biologies (Rituxan, Lemtrada, Remicade and Thymoglobuline)

* No national guidelines are in place

* GVHD remains a field of highly unattained unmet need

* No consensus over clinical trial endpoints

* Regulatory T cells (Tregs) are the focus of the early stage pipeline

* Huge opportunity exists in the chronic patient segment of GVHD

* Institutionally funded studies are the core of GVHD treatment management

For more information, or to buy the report ("OpportunityAnalyzer: Graft Versus Host Disease--Opportunity Analysis and Forecasts to 2018", Global Data, 252 pages, $7,995), visit the following link. Contact: http://goo.gl/zzt6Y0

COPYRIGHT 2014 DataTrends Publications, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2014 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Industry & Market Research
Publication:Stem Cell Business News
Date:Oct 6, 2014
Words:358
Previous Article:Cell isolation/separation market to be worth $5.1 b by 2019.
Next Article:Global stem cell therapy market growing at 39.5 percent CAGR.
Topics:

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |